Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease
Posted by amanda punzalan under Press (No Respond)
Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease Significant Reductions of Disease Manifestations in Proprietary Mouse Renal Model of APOL1-Mediated Kidney Disease Observed New Research Shows APOL1 p.N264K Variant Associated…